EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review

Mohammed Yousef Almulhim iD

PLOS ONE · 29.01.2025 · 20 (1) · e0311755

DOI: 10.1371/journal.pone.0311755 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS ONE, online erschienen am 29.01.2025. Verfasst von Mohammed Yousef Almulhim. Beteiligte Einrichtung: College of Medicine, King Faisal University, Alahsa, Saudi Arabia. Hauptthemen laut MEDLINE: Acute Kidney Injury, Biomarkers. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Faisal University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute kidney injury (AKI) is a frequent clinical complication lacking early diagnostic tests and effective treatments. Novel biomarkers have shown promise for enabling earlier detection, risk stratification, and guiding management of AKI. We conducted a systematic review to synthesize evidence on the efficacy of novel biomarkers for AKI detection and management. Database searches yielded 17 relevant studies which were critically appraised. Key themes were biomarker efficacy in predicting AKI risk and severity before functional changes; potential to improve clinical management through earlier diagnosis, prognostic enrichment, and guiding interventions; emerging roles as therapeutic targets and prognostic tools; and ongoing challenges requiring further validation. Overall, novel biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cell cycle arrest markers ([TIMP-2] •[IGFBP7]) demonstrate capability for very early AKI prediction and accurate risk stratification. Their incorporation has potential to facilitate timely targeted interventions and personalized management. However, factors influencing biomarker performance, optimal cutoffs, cost-effectiveness, and impact on patient outcomes require robust validation across diverse settings before widespread implementation. Addressing these limitations through ongoing research can help translate novel biomarkers into improved detection, prognosis, and management of AKI in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryBiomarkersHumansEarly DiagnosisPrognosisHepatitis A Virus Cellular Receptor 1Lipocalin-2Tissue Inhibitor of Metalloproteinase-2Insulin-Like Growth Factor Binding Proteins

Substanzen

BiomarkersHepatitis A Virus Cellular Receptor 1Lipocalin-2insulin-like growth factor binding protein-related protein 1HAVCR1 protein, humanTissue Inhibitor of Metalloproteinase-2Insulin-Like Growth Factor Binding Proteins

Autor:innen und Institutionen

  • College of Medicine, King Faisal University, Alahsa, Saudi Arabia.

ORCID-Profile: Mohammed Yousef Almulhim

Förderung

  • King Faisal University

Zitieren

APA

Yousef Almulhim, M. (2025). The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review. PLOS ONE, 20(1), e0311755. https://doi.org/10.1371/journal.pone.0311755

Vancouver

Yousef Almulhim M. The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review. PLOS ONE. 2025;20(1):e0311755. doi:10.1371/journal.pone.0311755

BibTeX
@article{YousefAlmulhim2025,
  author = {Yousef Almulhim, Mohammed},
  title = {The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {1},
  pages = {e0311755},
  doi = {10.1371/journal.pone.0311755}
}
Kostenlos starten →